Highlights

• Sonic Healthcare gained 0.36% to $19.37 on 4 September 2026

• H1 FY2026 Revenue reached A$5.445 billion, up 17% year-on-year

• H1 EBITDA of A$907 million, up 10%

• Net profit rose 11% to A$262 million in H1 FY2026

Sonic Healthcare Ltd (ASX:SHL) posted a modest gain of 0.36% to $19.37 on 4 September 2026. The global pathology and diagnostic imaging group continues to demonstrate steady growth across its diversified operations, with its half-year results showing solid revenue and Earnings momentum.

About the Company

Sonic Healthcare is one of the world's largest pathology companies, with operations spanning Australia, the United States, Europe and the United Kingdom. The company provides laboratory testing, diagnostic imaging, and general practice services. Sonic has built its global presence through a strategy of acquiring high-quality pathology businesses and integrating them under its federated management model. It is one of the largest ASX-listed healthcare companies by revenue.

Key Developments

Sonic Healthcare reported FY2026 full-year financial information following its preliminary final report released on 20 August 2026. Earlier FY2026 half-year results showed revenue of A$5.445 billion, up 17%, EBITDA of A$907 million, up 10%, and net profit of A$262 million, up 11%. Operating cash generation reached A$682 million.

Key Catalysts to Watch

• Full-year FY2026 result and any updated Dividend or earnings guidance

• Volume growth in pathology testing across key markets including Germany and the US

• Acquisition opportunities in European or North American pathology markets

• Recovery in GP and specialist referral volumes post-COVID normalisation

Risks

• Softening of COVID-related testing revenues affecting year-on-year comparisons

• Labour cost pressures in pathology collection and laboratory operations

• Currency headwinds given significant international operations in EUR and USD

• Competition and pricing pressure in the pathology testing market

Conclusion

Sonic Healthcare's half-year results highlight the underlying resilience of its global pathology business, with 17% revenue growth and double-digit profit improvement. The company's diversified geographic footprint provides stability and opportunities for further acquisition-led growth. The modest gain on 4 September reflects a steady-state environment for the stock. Investors will look to the full-year result and any guidance for FY2027 to assess whether the growth trajectory is sustainable.